CN102718855B - Anti-Pf 332-DBL sectional monoclonal antibody capable of inhibiting invasion of plasmodium falciparum - Google Patents
Anti-Pf 332-DBL sectional monoclonal antibody capable of inhibiting invasion of plasmodium falciparum Download PDFInfo
- Publication number
- CN102718855B CN102718855B CN2012101768796A CN201210176879A CN102718855B CN 102718855 B CN102718855 B CN 102718855B CN 2012101768796 A CN2012101768796 A CN 2012101768796A CN 201210176879 A CN201210176879 A CN 201210176879A CN 102718855 B CN102718855 B CN 102718855B
- Authority
- CN
- China
- Prior art keywords
- dbl
- monoclonal antibody
- plasmodium falciparum
- lys
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses an anti-Pf 332-DBL sectional monoclonal antibody capable of inhibiting invasion of plasmodium falciparum. The anti-Pf 332-DBL sectional monoclonal antibody can be specifically bound with DBL sectional functional polypeptide of a Pf 332 membrane protein of the plasmodium falciparum, wherein the DBL sectional functional polypeptide of the Pf 332 membrane protein of the plasmodium falciparum has the amino acid sequence as shown in SEQ ID No.2. The anti-Pf 332-DBL sectional monoclonal antibody can be obtained through a method that splenocyte is fused with an Sp 2/0 cell by using a DBL recombinant protein immunized mouse with an His label, and the DBL recombinant protein with a GST label is adopted for initially selecting, and the functional polypeptide is adopted for positive selecting. The anti-Pf 332-DBL sectional monoclonal antibody has a powerful function of inhibiting the invasion of polypide, and the function is stronger than that of an MP antibody which is purified from Mali human serum that is infected by the plasmodium falciparum; a monoclonal antibody incapable of being specifically bound with the functional polypeptide has relatively weak or no function of inhibiting the invasion of the polypide; and the DBL sectional functional polypeptide can be applied to the research and development of therapeutic polypeptide drugs for malaria and the development of preventive polypeptide vaccine.
Description
The application is on 05 18th, 2010 applying date, application number 201010174866.6, the dividing an application of application for a patent for invention that denomination of invention is a kind of to suppress the anti-Pf332-DBL region monoclonal antibody that plasmodium falciparum invades.
Technical field:
The present invention relates to parasitology and field of immunology.More specifically, the present invention relates to a kind of anti-Pf332-DBL region monoclonal antibody and plasmodium falciparum Pf332 membrane protein DBL district functional polypeptide that plasmodium falciparum is invaded that suppress
Background technology:
The drug-fast generation of plasmodium and diffusion have made global malaria the epidemic situation was severe and worsened, annual malaria death toll from last century the seventies about 500,000 rise at present approximately 1,000,000, the measure of medical treatment malaria also faces serious difficulty and challenge.Therefore the enforcement of new malaria measure of control has become the task of top priority.Vaccine inoculation has made many kinds of transmissible diseases be controlled effectively and even has eradicated, and therefore developing effective malaria vaccine becomes the important means that prevents that plasmodium from infecting.Pf332 albumen is synthetic by plasmodium, be transported to the erythrocyte surface of infection by typical golgi body Secretory Pathway, because being distributed to, it infects erythrocyte surface when the erythrocytic stage plasmodium grows late period, infer that it may be by the erythrocytic permeability of influence, the change of plasticity-and relevant function promotes the cracking of erythrocyte membrane and the release of merozoite.The Pf332 genes encoding is rich in the repeated fragment of L-glutamic acid in a large number, wherein pentapeptide molecule VTEEI(V) be the epi-position that can be neutralized antibody recognition.Pf332 albumen exists a plurality of B, t cell epitope, can be identified by human body widely, and induce human body to produce higher antibody titers.Recently, there are some researches prove and identify that the Pf332 gene is made up of two exons.Exon
The Duffy-binding-like district of being rich in halfcystine polypeptide segment and plasmodium falciparum EBL family of coding has high similarity.It is not only very conservative to be distributed in this section Pf332-DBL district that infects outside the erythrocyte membrane, and in the various plasmodium falciparum worm strain such as 3D7AH1, FCR3S1.2,7G8 expression is arranged all.In addition, the expression amount of Pf332 albumen and polypide proliferation rate are proportional in the vitro culture, and the polyclonal antibody in anti-Pf332-DBL district can significantly reduce the intrusion rate of various worm strains.Invade erythrocytic important molecule Pf332 as potential auxiliary plasmodium falciparum merozoite, because the outer DBL district of its film compares the conservative property of height with other film outskirt protein, make it become the new antimalarial agent of development and the candidate molecules of vaccine, therefore the research to its function and biological action becomes particularly important.
The characteristics of monoclonal antibody are: physicochemical character height homogeneous, biological activity high specificity single, that be combined with antigen, be convenient to artificial the processing and quality control, and the source easily.These advantages make it be paid much attention to once coming out, and become the main means of many significant problems such as solving biology and medical science.By preparing monoclonal antibody and analyzing its function, not only can study the main biological action of protein, can also the binding peptide scanning technique screen the critical area that protein is implemented function.
The monoclonal antibody of anti-plasmodium falciparum protein is widely used in the research of functional protein biological action.And at present about the MONOCLONAL ANTIBODIES SPECIFIC FOR in anti-plasmodium falciparum Pf332 membrane protein DBL district and can suppress polypide and invade the screening of erythrocytic monoclonal antibody and do not appear in the newspapers.
Summary of the invention:
The purpose of this invention is to provide plasmodium falciparum Pf332 membrane protein DBL district functional polypeptide, its aminoacid sequence is shown in SEQ ID No.2;
Another object of the present invention provides a kind of anti-Pf332-DBL region monoclonal antibody that plasmodium falciparum is invaded that suppresses, it can with, the plasmodium falciparum Pf332 membrane protein DBL district functional polypeptide specificity combination of its aminoacid sequence shown in SEQ ID No.2;
A kind of preparation method who suppresses the anti-Pf332-DBL region monoclonal antibody of plasmodium falciparum intrusion of the present invention may further comprise the steps:
1) Pf332-DBL district gene is inserted among the carrier pQE70 of band His label, make up plasmid pQE-DBL, and transfection is expressed the DBL recombinant protein of band His label to engineering bacteria M15;
2) with the DBL recombinant protein immune mouse of band His label, the aseptic mouse spleen of winning with splenocyte and Sp2/0 cytogamy, gets hybridoma cell strain under the effect of PEG1450;
3) the DBL fragment is connected on the pGEX-4T-1 carrier of band GST label, and is transformed into BL21(DE3) in, the DBL recombinant protein of being with the GST label expressed; Step 2) hybridoma cell strain of Huo Deing carries out positive-selecting with the DBL recombinant protein of band GST label, filters out the hybridoma cell strain that can secrete anti-Pf332-DBL district monoclonal antibody;
4) the positive hybridoma cell strain that filters out is carried out positive-selecting with above-mentioned plasmodium falciparum Pf332 membrane protein DBL district functional polypeptide again, and the positive is a kind of anti-Pf332-DBL region monoclonal antibody that plasmodium falciparum is invaded that suppresses.
A kind of anti-Pf332-DBL region monoclonal antibody that suppresses the plasmodium falciparum intrusion is that the hybridoma cell strain branch that is numbered Anti-332-mAb8 or Anti-332-mAb7 oozes.
Plasmodium falciparum Pf332 membrane protein DBL of the present invention district functional polypeptide, the application in the therapeutical peptide medicine of production malaria and control property polypeptide vaccine.
The present invention is template with plasmodium falciparum cDNA, pass through pcr amplification, obtain the Pf332-DBL gene fragment, it is connected respectively among His label fusion expression vector pQE-70 and the GST label fusion expression vector pGEX-4T-1, transform corresponding host bacterium more respectively, carry out His label recombinant protein and GST label Recombinant Protein Expression and purifying, difference called after DBL-His and DBL-GST, for avoiding in the monoclonal antibody preparation process, screening false positive monoclonal antibody (i.e. anti-His tag antibody), use DBL-His to make immunizing antigen, DBL-GST makes the detection antigen of screening usefulness.Use the DBL-His immune mouse, the DBL-GST bag is detected antibody titer by elisa plate, obtains the monoclonal antibody in anti-plasmodium falciparum Pf332 membrane protein DBL district by conventional monoclonal antibody technology of preparing.According to the synthetic in proper order 9 sections polypeptide of Pf332-DBL region amino acid sequence, with the polypeptide bag by elisa plate, by pepscan the zone of the monoclonal antibody identification that obtains is analyzed, each strain of monoclonal antibody of choosing the identification different zones is more respectively carried out the vitro inhibition plasmodium falciparum and is invaded erythrocytic experiment.Screened to have and suppressed the monoclonal antibody that polypide is invaded function more by force, found the major function district polypeptide segment in Pf332 membrane protein DBL district.
The present invention is a kind of to suppress the anti-Pf332-DBL region monoclonal antibody that plasmodium falciparum is invaded, can with plasmodium falciparum Pf332 membrane protein DBL district functional polypeptide, its aminoacid sequence shown in SEQ ID No.2, the specificity combination; It is by the DBL recombinant protein immune mouse with band His label, under the effect of PEG1450 with splenocyte and Sp2/0 cytogamy, with the DBL recombinant protein primary election of band GST label, carry out the method acquisition of positive-selecting again with plasmodium falciparum Pf332 membrane protein DBL district functional polypeptide; Have and suppress polypide more by force and invade function, and be higher than from infection the MP antibody of purifying the Mali human serum of plasmodium falciparum is arranged; The monoclonal antibody that can not be combined with its specificity, suppressing polypide, to invade function lower or do not have this function.
Under the effect of 0.5mg/mL monoclonal antibody, the monoclonal antibody of the mAb8 secretion that can be combined with the 1st section (its aminoacid sequence is shown in SEQ ID No.1) specificity, polypide intrusion rate is 18%; The monoclonal antibody that can secrete with the mAb7 of the 4th section polypeptide (its aminoacid sequence is shown in SEQ ID No.2) combination is 30%, and have the MP antibody of purifying the Mali human serum of plasmodium falciparum to have only 35% from infection, show that this two strains monoclonal antibody has very strong inhibition polypide and invades erythrocytic function; Plasmodium falciparum Pf332 membrane protein DBL district functional polypeptide can be applied to the research and development of therapeutical peptide medicine of malaria and the development of control property polypeptide vaccine.
Description of drawings
The recombinant antigen SDS-PAGE of Fig. 1 purifying analyzes, M: dye marker in advance; The 1:DBL-His recombinant protein; The 2:DBL-GST recombinant protein.
The recombinant antigen Western bloting of Fig. 2 purifying analyzes, the A:DBL-GST recombinant protein; The B:DBL-His recombinant protein;
The 1:Anti-GST monoclonal antibody is made primary antibodie; The how anti-primary antibodie of doing of 2:Anti-Pf332-DBL; The 3:Anti-His monoclonal antibody is made primary antibodie; The how anti-primary antibodie of doing of 4:Anti-Pf332-DBL.
The Western bloting of Fig. 3 monoclonal antibody specific recognition recombinant antigen DBL-GST analyzes, M: dye marker in advance; 1-12:Anti-332- mAb 1,2,3,4, and 5,6,7,8,9,10,11,12 make primary antibodie.
The Western bloting of Fig. 4 monoclonal antibody specific recognition native protein Pf332 analyzes, M: dye marker "+" in advance: polypide albumen; "-": normoerythrocyte albumen.
The indirect immunofluorescence analysis of Fig. 5 monoclonal antibody specific recognition native protein Pf332, (A): Anti-GST monoclonal antibody and Anti-332- mAb 1,2,3,4,5,6 make primary antibodie; (B): Anti-332- mAb 7,8,9,10, and 11,12 make primary antibodie.
Embodiment
The following example is intended to further describe for example the present invention, rather than limits the present invention by any way.Under the prerequisite that does not deviate from the spirit and principles in the present invention, any change or change that those of ordinary skills that the present invention is done realize easily all will fall within the claim scope that awaits the reply of the present invention.
The structure of recombinant expression vector pQE-DBL and pGEX-4T-1-DBL
In this embodiment, according to the Pf332-DBL region nucleotide sequence, synthetic following PCR primer:
Upstream primer is: 5 '-GCGAATTCAGCAACATCAACAACAAGG-3 ';
Downstream primer is: 5 '-GCGCGGCCGCTTAGGCGTACTTCTTCTCGA-3 '
Be template with plasmodium falciparum cDNA, carry out pcr amplification by above-mentioned primer, obtain the Pf332-DBL gene fragment, its nucleotide sequence is connected among the His label fusion expression vector pQE-70 shown in SEQ ID No.3, and structure obtains
Recombinant expression vector pQE-DBL is with the expression of the recombinant protein DBL-His that contains the His label.
Be template with plasmodium falciparum cDNA, carry out pcr amplification by above-mentioned primer, obtain the Pf332-DBL gene fragment, be connected among the GST label fusion expression vector pGEX-4T-1, structure obtains recombinant expression vector pGEX-4T-1-DBL, with the expression of the recombinant protein DBL-GST that contains the GST label.
For avoiding in the monoclonal antibody preparation process, screening false positive monoclonal antibody (i.e. anti-His tag antibody), use DBL-His to make immunizing antigen, DBL-GST makes the detection antigen of screening usefulness.
The expression of recombinant antigen DBL-His and DBL-GST and purifying
Recombinant expression vector pQE-DBL among the embodiment 1 and pGEX-4T-1-DBL are transformed into respectively in M15 and BL21 (DE3) the host bacterium, after carrying out abduction delivering respectively, by affinity chromatography difference purifying DBL-His and DBL-GST recombinant antigen, carry out SDS-PAGE and analyze (as Fig. 1).With the how anti-primary antibodie of doing in the mouse source of anti-His label monoclonal antibody or anti-GST label monoclonal antibody and anti-Pf332-DBL recombinant protein is carried out Western bloting evaluation, have specific band (as Fig. 2) respectively at 28kDa and 52kDa place.Its aminoacid sequence of DBL-His is shown in SEQ ID No.4, and its aminoacid sequence of DBL-GST is shown in SEQ ID No.5.
The preparation of anti-plasmodium falciparum Pf332 membrane protein DBL region monoclonal antibody
(1) animal immune
Immunization protocol adopts the method for long period heavy dose to carry out.Get 56 ~ 8 age in week female BALB/c mouse, head exempts to adopt the immunizing antigen DBL-His of purifying among the embodiment 2 to mix with the equivalent Freund's complete adjuvant, the complete pneumoretroperitoneum of emulsification is injected, dosage is every mouse 50 μ g immunizing antigens.Every 3 all immunity once, dosage is constant afterwards, and adjuvant is changed to Freund's incomplete adjuvant.10 ~ 14 days tail vein bloods after each immunity, separation of serum satisfies cytogamy until antibody titer and requires (1:5 * 10 by indirect elisa method (the detection antigen DBL-GST of purifying bag is by elisa plate among the embodiment 2) detection specificity antibody titer
4More than).Merged preceding 3 days, the pure antigen of intraperitoneal injection of mice 25 μ g carries out booster immunization; 24h before merging, the mouse fasting;
(2) preparation of hybridoma cell strain
In immune mouse, prepare mouse myeloma Sp2/0 cell, get the mouse spleen behind the booster immunization and prepare splenocyte.Splenocyte and Sp2/0 cell are put into the glass centrifuge tube by the mixed of 5:1 ~ 10:1, and the centrifugal 5min of 1000 * g abandons supernatant, flicks the centrifuge tube mixing with finger; Dropwise splash into 0.8mL 50% PEG solution, with dropper pressure-vaccum 5～6 times gently, behind the 30s, the centrifugal 3min of 700 * g; Dropwise slowly add the incomplete substratum of 20mL, dilution PEG loses it and urgees to melt effect, the centrifuge tube bottom is done draw a circular motion, and behind the 2min, the centrifugal 5min of 1000 * g abandons supernatant, washes once with method again; Slowly add 50mL HAT substratum, mixing joins and spreads on the 96 porocyte culture plates that make feeder layer cells (Turnover of Mouse Peritoneal Macrophages) gently, and every hole adds 0.1mL cytogamy suspension, places 37 ℃, 5% CO
2Cultivate in the incubator; After 24 hours, 0.05mL HAT substratum is added in every hole, and respectively at the 4th day, 7 days and 10 days, changes the HAT substratum according to the cell growing state;
(3) screening of hybridoma cell strain
Observe under 100 times of mirrors, treat that the fused cell colony grows to 1/2 visual field when above, by indirect elisa method (detecting antigen DBL-GST bag by elisa plate) hybridoma cell strain that occurs in the culture hole is carried out positive-selecting, namely filter out the hybridoma cell strain that to secrete anti-Pf332-DBL district monoclonal antibody;
(4) clone of hybridoma cell strain
Blow afloat gently with the HT substratum fused cell that detected result is positive and to be transferred to 24 orifice plates, 10 times of dilutions, cell counting; Carry out getting mixing in 100 cells adding 10mL HT substratum after 10 times of dilutions again, this cell suspension is splashed in 96 well culture plates of spreading feeder layer cells processed, every hole 0.1mL places 5% CO
2Incubator, 37 ℃ of cultivations; Do not want the migratory cell culture plate in preceding 3 days, and in order to avoid make cell dissociation, observed every porocyte colony in the time of the 4th day, holes single, a plurality of cell clones are made mark respectively and changed liquid once, change the HT substratum again according to the cell growing state in the time of the 7th, 10 day; Observe under 100 times of mirrors, treat that monoclonal cell colony grows to 1/2 visual field when above, detects the supernatant antibody titer, to positive cell time cloning again, when all clone cell holes are all positive till, finally obtain hybridoma that 12 strains can stably excreting monoclonal antibody called after Anti-332-mAb 1 respectively, 2,3,4,5,6,7,8,9,10,11,12.
(5) a large amount of preparations of monoclonal antibody
Autoclaved paraffin oil is expelled to mouse peritoneal, 0.5mL/, 1 every mouse peritoneal injection 2 * 10 in week back
6Individual hybridoma, injection cell extracted ascites after 8～10 days when mouse web portion expands and is slow in action, 37 ℃ of incubations are after 1 hour, and 4 ℃ are spent the night, and the centrifugal 10min of 4000 * g discards fat, clarification ascites in the middle of collecting, and packing is frozen standby.
(6) Purification of Monoclonal Antibodies
Adopt ProteinA affinity chromatography purifying from mouse ascites to obtain monoclonal antibody.
(7) hypotype of monoclonal antibody classification
Identify the immunoglobulin (Ig) of monoclonal antibody with monoclonal antibody hypotype classification identification kit (SIGMA) by indirect elisa method
Type and hypotype, 12 strain monoclonal antibodies are the IgG1 type.
The evaluation of anti-plasmodium falciparum Pf332 membrane protein DBL region monoclonal antibody
With the Anti-332-mAb1 of preparation among the embodiment 3,2,3,4,5,6,7,8,9,10,11,12 monoclonal antibodies detect recombinant antigen DBL-GST by conventional Western bloting experiment.The result shows under the 12 strain monoclonal antibody effects, at the 52kDa place, a tangible band (as Fig. 3) to be arranged all, shows that the monoclonal antibody that makes all can be combined with recombinant antigen DBL-GST specificity.
Use Anti-332-mAb1,2,3,4,5,6,7,8,9,10,11,12 monoclonal antibodies detect the expression of plasmodium falciparum polypide natural protein Pf332 by conventional Western bloting experiment.The result shows, under the 12 strain monoclonal antibody effects, polypide albumen is the specific band that has occurred on the swimming lane of sample solution greater than 250kDa, and do not have band (as Fig. 4) at the swimming lane that with normal people's red corpuscle is sample solution, show that the monoclonal antibody that makes all can be combined with polypide natural protein Pf332 specificity.
Use Anti-332-mAb1,2,3,4,5,6,7,8,9,10,11,12 monoclonal antibodies detect the expression of plasmodium falciparum polypide natural protein Pf332 by conventional indirect immunofluorescence experiment.Through the red corpuscle that the Hoechst dyestuff was redyed, as infecting polypide, polypide just is blue-fluorescence in born of the same parents, because red corpuscle does not have nucleic acid substances, therefore, normoerythrocyte does not present fluorescence.The result shows, dye the interior polypide of dried female insect cell and be blue-fluorescence, and with 12 strain monoclonal antibodies be the primary antibodie effect dye the dried female insect cell, on the polypide surface or erythrocyte surface all in various degree present green fluorescence, and the dried female insect cell that dyes of anti-GST monoclonal antibody effect does not present green fluorescence (as Fig. 5), shows that this 12 strain monoclonal antibody all can the combination of polypide natural protein Pf332 specificity.
Embodiment 5
Determining of anti-plasmodium falciparum Pf332 membrane protein DBL region monoclonal antibody identified region
According to the Pf332-DBL region amino acid sequence, be one section polypeptide with 25 amino acid, order is divided into 9 sections polypeptide, and wherein the final stage peptide is 16 amino acid, gives birth to the synthetic and coupling BSA of worker biotech firm by Shanghai.Carry out pepscan by indirect elisa method, and then the peptide section at definite monoclonal antibody identification epi-position place.With 9 sections synthetic polypeptide dilutions, respectively with 5 μ g/mL, the every hole of 50 μ L bag is added the anti-Pf332-DBL district monoclonal antibody of 1000 times of dilutions as primary antibodie by elisa plate, reacts and measures OD
405Value, the maximum hole of value is corresponding monoclonal antibody binding peptide section.All hole OD
405Be worth all less than 0.2 o'clock any peptide section of this monoclonal antibody debond.The result shows that have 9 strain monoclonal antibodies to be respectively in conjunction with 4 sections polypeptide: the monoclonal antibody in conjunction with the 1st section polypeptide is mAb3, mAb4, mAb8; Monoclonal antibody in conjunction with the 4th section polypeptide is mAb7; Monoclonal antibody in conjunction with the 6th section polypeptide is mAb5, mAb10, mAb11, mAb12; Monoclonal antibody in conjunction with the 7th section polypeptide is mAb1; MAb2, mAb6, any peptide section of mAb9 debond may be because the zone of their institute's combinations is the linking district of polypeptide segment.
Screening with the anti-plasmodium falciparum Pf332 membrane protein DBL region monoclonal antibody that presses down the worm effect:
(1) the plasmodium falciparum polypide after the synchronization cultivation is carried out microscopy, be in the late trophozoites phase as major part, just calculate the worm rate of dying, and get the centrifugal 5min of polypide culture 1000r/min, abandon supernatant, be diluted to normoerythrocyte suspension and perfect medium that to dye the worm rate be 1%, pcv is 2% again;
(2) above-mentioned dilution is good polypide culture joins in 96 well culture plates, every hole 75 μ L;
(3) choose in conjunction with the 1st, 4,6, each strain of the monoclonal antibody of 7 sections polypeptide and debond polypeptide, be respectively mAb8, mAb7, mAb5, mAb1 and mAb9, carry out the different multiples dilution with perfect medium, it is joined in the hole with polypide culture, every hole 25 μ L, final concentration was after every strain monoclonal antibody added in the hand-hole: 0.5mg/mL, 0.13 mg/mL, 0.03 mg/mL, each concentration of every strain monoclonal antibody is all established two repeating holes, be the positive contrast of MP antibody (antibody of purifying the Mali human serum of plasmodium falciparum being arranged from infection) of 0.5mg/mL with the final concentration, with the negative contrast of IgG in the immune serum not, final concentration also is: 0.5mg/mL, 0.13 mg/mL, 0.03 mg/mL, positive control and negative control are all established repeating hole, simultaneously, other holes add 25 μ L perfect mediums and organize in contrast;
(4) behind the cultivation 24h, get the polypide culture and count with acridine orange dyeing and by flow cytometer, measure 5 * 10 at every turn
4Individual cell;
(5) this experiment triplicate, the worm rate of dying that records is calculated relative intrusion rate by following formula.
Intrusion rate=test set is dyed worm rate/control group and is dyed the worm rate relatively
The result shows, and is minimum with the relative intrusion rate of polypide under the mAb7 effect with the mAb8 of the 4th section polypeptide in conjunction with the 1st section respectively, is specially under the effect of 0.5mg/mL monoclonal antibody: mAb8:18%; MAb7: 30%, be lower than 35% under the effect of 0.5mg/mL MP antibody, show that this two strains monoclonal antibody has very strong inhibition polypide and invades erythrocytic function, these corresponding two sections peptide zones are key areas that Pf332-DBL implements biological function.
Embodiment 7
A kind of preparation method who suppresses the anti-Pf332-DBL region monoclonal antibody of plasmodium falciparum intrusion
1) Pf332-DBL district gene is inserted among the carrier pQE70 of band His label, make up plasmid pQE-DBL, and transfection is expressed the DBL recombinant protein of band His label to engineering bacteria M15;
2) with the DBL recombinant protein immune mouse of band His label, the aseptic mouse spleen of winning with splenocyte and Sp2/0 cytogamy, gets hybridoma cell strain under the effect of PEG1450;
3) the DBL fragment is passed through the PCR subclone to the pGEX-4T-1 carrier of band GST label, and is transformed into BL21(DE3) in, the DBL recombinant protein of being with the GST label expressed; Step 2) hybridoma cell strain of Huo Deing carries out positive-selecting with the DBL recombinant protein of band GST label, filters out the hybridoma cell strain that can secrete anti-Pf332-DBL district monoclonal antibody;
4) the positive hybridoma cell strain that filters out, again with above-mentioned plasmodium falciparum Pf332 membrane protein DBL district functional polypeptide, the 1st section (its aminoacid sequence is shown in SEQ ID No.1) or the 4th section polypeptide (its aminoacid sequence is shown in SEQ ID No.2) carry out positive-selecting, and positive both had been a kind of anti-Pf332-DBL region monoclonal antibody that plasmodium falciparum is invaded that suppresses.
＜110〉Jilin University
＜120〉a kind of anti-Pf332-DBL region monoclonal antibody that suppresses the plasmodium falciparum intrusion.
<160> 5
<210> 1
<211> 25
<212> PRT
＜213〉artificial
<400> 1
Ser Asn Ile Asn Asn Lys Asp Ser Ser Thr Glu Trp Asn Cys Lys Glu
1 5 10 15
Asp Val Gly Cys Val Pro Pro Arg Arg
20 25
<210> 2
<211> 25
<212> PRT
＜213〉artificial
<400> 2
Asn Arg Ser Leu Ala Asp Tyr Lys Asp Ile Phe Gln Gly Lys Asp Met
1 5 10 15
Trp Asn Asp Gly Lys Tyr Gly Glu Ala
20 25
<210> 3
<211> 648
<212> DNA
＜213〉artificial
<400> 3
agcaacatca acaacaagga cagcagcacc gagtggaact gtaaggagga tgtgggctgt 60
gtccctccta ggcggcagaa cctgaacatg gagcggctgg acaacgagaa cgaggacagc 120
gtgcccgact tcatgaagaa aaccttctac ctggccgccg ccggcgaggg caagaagctg 180
agggagaagc acgacgagag ctgtgacgag ttctgtgacg cctggaacag aagcctggcc 240
gactacaagg acatcttcca gggcaaggac atgtggaacg acggcaagta cggggaggcc 300
aagaaccaca tcaagaacgc cttcggcgac atgaacaaca gaaagaccat gctgaacgag 360
atcgagaagg gcatcaagga cgagaccttc agcagagaaa acggcctgga tgtgtgtaag 420
agccagtgtg aggagagaag cagggacgac accgaggacc agttcctgag attcttcgcc 480
gagtgggagg aggagttttg tgacggcctg aataagcacg aggagcagct gaagagctgt 540
accaaggaca tcaactgtga catcaagtgc tccaacttca aggactggct ggagaccaag 600
aaggacgagt acgacatcca gagccgggtg ttcgagaaga agtacgcc 648
<210> 4
<211> 222
<212> PRT
＜213〉artificial
<400> 4
Ser Asn Ile Asn Asn Lys Asp Ser Ser Thr Glu Trp Asn Cys Lys Glu
1 5 10 15
Asp Val Gly Cys Val Pro Pro Arg Arg Gln Asn Leu Asn Met Glu Arg
20 25 30
Leu Asp Asn Glu Asn Glu Asp Ser Val Pro Asp Phe Met Lys Lys Thr
35 40 45
Phe Tyr Leu Ala Ala Ala Gly Glu Gly Lys Lys Leu Arg Glu Lys His
50 55 60
Asp Glu Ser Cys Asp Glu Phe Cys Asp Ala Trp Asn Arg Ser Leu Ala
65 70 75 80
Asp Tyr Lys Asp Ile Phe Gln Gly Lys Asp Met Trp Asn Asp Gly Lys
85 90 95
Tyr Gly Glu Ala Lys Asn His Ile Lys Asn Ala Phe Gly Asp Met Asn
100 105 110
Asn Arg Lys Thr Met Leu Asn Glu Ile Glu Lys Gly Ile Lys Asp Glu
115 120 125
Thr Phe Ser Arg Glu Asn Gly Leu Asp Val Cys Lys Ser Gln Cys Glu
130 135 140
Glu Arg Ser Arg Asp Asp Thr Glu Asp Gln Phe Leu Arg Phe Phe Ala
145 150 155 160
Glu Trp Glu Glu Glu Phe Cys Asp Gly Leu Asn Lys His Glu Glu Gln
165 170 175
Leu Lys Ser Cys Thr Lys Asp Ile Asn Cys Asp Ile Lys Cys Ser Asn
180 185 190
Phe Lys Asp Trp Leu Glu Thr Lys Lys Asp Glu Tyr Asp Ile Gln Ser
195 200 205
Arg Val Phe Glu Lys Lys Tyr Ala His His His His His His
210 215 220 222
<210> 5
<211> 449
<212> PRT
＜213〉artificial
<400> 5
Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro Thr
1 5 10 15
Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu Tyr
20 25 30
Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu Gly
35 40 45
Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys Leu
50 55 60
Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn Met
65 70 75 80
Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu Gly
85 90 95
Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser Lys
100 105 110
Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu Met
115 120 125
Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn Gly
130 135 140
Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp Val
145 150 155 160
Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu Val
165 170 175
Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr Leu
180 185 190
Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala Thr
195 200 205
Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Val Pro Arg Gly
210 215 220
Ser Pro Glu Phe Ser Asn Ile Asn Asn Lys Asp Ser Ser Thr Glu Trp
225 230 235 240
Asn Cys Lys Glu Asp Val Gly Cys Val Pro Pro Arg Arg Gln Asn Leu
245 250 255
Asn Met Glu Arg Leu Asp Asn Glu Asn Glu Asp Ser Val Pro Asp Phe
260 265 270
Met Lys Lys Thr Phe Tyr Leu Ala Ala Ala Gly Glu Gly Lys Lys Leu
275 280 285
Arg Glu Lys His Asp Glu Ser Cys Asp Glu Phe Cys Asp Ala Trp Asn
290 295 300
Arg Ser Leu Ala Asp Tyr Lys Asp Ile Phe Gln Gly Lys Asp Met Trp
305 310 315 320
Asn Asp Gly Lys Tyr Gly Glu Ala Lys Asn His Ile Lys Asn Ala Phe
325 330 335
Gly Asp Met Asn Asn Arg Lys Thr Met Leu Asn Glu Ile Glu Lys Gly
340 345 350
Ile Lys Asp Glu Thr Phe Ser Arg Glu Asn Gly Leu Asp Val Cys Lys
355 360 365
Ser Gln Cys Glu Glu Arg Ser Arg Asp Asp Thr Glu Asp Gln Phe Leu
370 375 380
Arg Phe Phe Ala Glu Trp Glu Glu Glu Phe Cys Asp Gly Leu Asn Lys
385 390 395 400
His Glu Glu Gln Leu Lys Ser Cys Thr Lys Asp Ile Asn Cys Asp Ile
405 410 415
Lys Cys Ser Asn Phe Lys Asp Trp Leu Glu Thr Lys Lys Asp Glu Tyr
420 425 430
Asp Ile Gln Ser Arg Val Phe Glu Lys Lys Tyr Ala Arg Pro His Arg
435 440 445
Asp
449
Claims (3)
1. plasmodium falciparum Pf332 membrane protein DBL district functional polypeptide, its aminoacid sequence is shown in SEQ ID No.2.
2. can suppress the anti-Pf332-DBL region monoclonal antibody that plasmodium falciparum is invaded, it is characterized in that: it can be combined with the described plasmodium falciparum Pf332 of claim 1 membrane protein DBL district functional polypeptide specificity.
3. claim 2 is described suppresses anti-Pf332-DBL region monoclonal antibody that plasmodium falciparum invades and prevents and treats application in the malaria medicine in production.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101768796A CN102718855B (en) | 2010-05-18 | 2010-05-18 | Anti-Pf 332-DBL sectional monoclonal antibody capable of inhibiting invasion of plasmodium falciparum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101768796A CN102718855B (en) | 2010-05-18 | 2010-05-18 | Anti-Pf 332-DBL sectional monoclonal antibody capable of inhibiting invasion of plasmodium falciparum |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101748666A Division CN101863970B (en) | 2010-05-18 | 2010-05-18 | Anti-Pf332-DBL region monoclonal antibody capable of restraining invasion of plasmodiumfalciparum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102718855A CN102718855A (en) | 2012-10-10 |
| CN102718855B true CN102718855B (en) | 2013-08-14 |
Family
ID=46944746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101768796A Expired - Fee Related CN102718855B (en) | 2010-05-18 | 2010-05-18 | Anti-Pf 332-DBL sectional monoclonal antibody capable of inhibiting invasion of plasmodium falciparum |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102718855B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103965321B (en) * | 2013-01-28 | 2016-06-22 | 苏州偲聚生物材料有限公司 | Polypeptide, the detection device comprising this polypeptide and detection kit |
| CN113045653A (en) * | 2021-03-22 | 2021-06-29 | 中国人民解放军空军军医大学 | Monoclonal antibody for inhibiting plasmodium infection and preparation method and application thereof |
-
2010
- 2010-05-18 CN CN2012101768796A patent/CN102718855B/en not_active Expired - Fee Related
Non-Patent Citations (8)
| Title |
|---|
| Analysis of structure and function of the giant protein Pf332 in Plasmodium falciparum;Anthony N. Hodder et al;《Molecular Microbiology》;20081022;第71卷(第1期);全文 * |
| Anthony N. Hodder et al.Analysis of structure and function of the giant protein Pf332 in Plasmodium falciparum.《Molecular Microbiology》.2008,第71卷(第1期), |
| 单志新等.恶性疟原虫FCC1/HN株Pf332基因的克隆和测序.《中国人兽共患病杂志》.2001,(第06期), |
| 单志新等.恶性疟原虫红内期Pf332抗原基因未知序列的测定及分析.《中国生物化学与分子生物学报》.2002,(第04期), |
| 恶性疟原虫FCC1/HN株Pf332基因的克隆和测序;单志新等;《中国人兽共患病杂志》;20011220(第06期);全文 * |
| 恶性疟原虫红内期Pf332抗原基因未知序列的测定及分析;单志新等;《中国生物化学与分子生物学报》;20020810(第04期);全文 * |
| 恶性疟原虫膜蛋白Pf332-DBL区在毕赤酵母中的表达;杜承等;《中国生物制品学杂志》;20100331;第23卷(第3期);全文 * |
| 杜承等.恶性疟原虫膜蛋白Pf332-DBL区在毕赤酵母中的表达.《中国生物制品学杂志》.2010,第23卷(第3期), |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102718855A (en) | 2012-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109134665A (en) | A kind of BCMA Chimeric antigen receptor and application based on single domain antibody | |
| CN105968200A (en) | Anti-human pd-l1 humanized monoclonal antibody and application thereof | |
| CN110294807A (en) | Anti- TIM-3 antibody | |
| JPH10511085A (en) | Methods for promoting an immune response using bispecific antibodies | |
| CN102936284A (en) | Human antibodies against rabies and uses thereof | |
| CN102089324A (en) | Compositions and methods for the therapy and diagnosis of influenza | |
| CN102164962A (en) | Anti-GD2 antibodies and methods and uses related thereto | |
| CN102649818A (en) | CD4 protein-resistant monoclonal antibody and active fragment and application thereof | |
| CN102471382A (en) | TLR3 binding agents | |
| CN105461809B (en) | PCSK9 antibody, its medical composition and its use | |
| AU677221B2 (en) | A monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses | |
| CN107488230A (en) | A kind of antibody, encoding gene and the application of the extracellular end proteins of anti-human CD79a | |
| WO2018209265A1 (en) | Anti-malarial antibodies that bind circumsporozoite protein | |
| CN104829725A (en) | Construction and application of bispecific antibody CD133*CD3 | |
| CN102690789A (en) | Hybridoma cell strain secreting tetanus exotoxin monoclonal antibody, monoclonal antibody prepared by same, Fab antibody and application | |
| CN102453091B (en) | Tetanus toxoid monoclonal antibody and preparation method and application thereof | |
| CN103254312B (en) | Mouse monoclonal antibody and its preparation method and application thereof | |
| CN102718855B (en) | Anti-Pf 332-DBL sectional monoclonal antibody capable of inhibiting invasion of plasmodium falciparum | |
| CN101863970B (en) | Anti-Pf332-DBL region monoclonal antibody capable of restraining invasion of plasmodiumfalciparum | |
| CN100509849C (en) | Soluble human CD28 molecule detection kit and use thereof | |
| CN101864398B (en) | Monoclonal antibody of anti-gonadotropin-releasing hormone receptor and application thereof | |
| WO2023046097A1 (en) | Anti-tigit humanized antibody or antigen-binding fragment thereof and application thereof | |
| CN103214571B (en) | Murine monoclonal antibody and preparation method and application thereof | |
| US20240002500A1 (en) | Anti-TIGIT Antibody or Antigen-Binding Fragment Thereof | |
| CN102181402B (en) | Monoclonal antibody of high-pathogenicity porcine reproductive and respiratory syndrome (PRRS) virus and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130814 Termination date: 20140518 |